🎉 M&A multiples are live!
Check it out!

Inozyme Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Inozyme Pharma and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Inozyme Pharma Overview

About Inozyme Pharma

Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.


Founded

2015

HQ

United States of America
Employees

67

Website

inozyme.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$4.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Inozyme Pharma Financials

Inozyme Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Inozyme Pharma achieved revenue of n/a and an EBITDA of -$95.7M.

Inozyme Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Inozyme Pharma valuation multiples based on analyst estimates

Inozyme Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$67.0M -$95.7M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$67.1M -$71.2M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a $10.2M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Inozyme Pharma Stock Performance

As of April 15, 2025, Inozyme Pharma's stock price is $1.

Inozyme Pharma has current market cap of $62.3M, and EV of -$4.0M.

See Inozyme Pharma trading valuation data

Inozyme Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$4.0M $62.3M XXX XXX XXX XXX $-1.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Inozyme Pharma Valuation Multiples

As of April 15, 2025, Inozyme Pharma has market cap of $62.3M and EV of -$4.0M.

Inozyme Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Inozyme Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Inozyme Pharma and 10K+ public comps

Inozyme Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$4.0M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.0x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Inozyme Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Inozyme Pharma Valuation Multiples

Inozyme Pharma's NTM/LTM revenue growth is Infinity%

Inozyme Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Inozyme Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Inozyme Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Inozyme Pharma and other 10K+ public comps

Inozyme Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 43% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Inozyme Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Inozyme Pharma M&A and Investment Activity

Inozyme Pharma acquired  XXX companies to date.

Last acquisition by Inozyme Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Inozyme Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Inozyme Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Inozyme Pharma

When was Inozyme Pharma founded? Inozyme Pharma was founded in 2015.
Where is Inozyme Pharma headquartered? Inozyme Pharma is headquartered in United States of America.
How many employees does Inozyme Pharma have? As of today, Inozyme Pharma has 67 employees.
Who is the CEO of Inozyme Pharma? Inozyme Pharma's CEO is Dr. Douglas A. Treco, PhD.
Is Inozyme Pharma publicy listed? Yes, Inozyme Pharma is a public company listed on NAS.
What is the stock symbol of Inozyme Pharma? Inozyme Pharma trades under INZY ticker.
When did Inozyme Pharma go public? Inozyme Pharma went public in 2020.
Who are competitors of Inozyme Pharma? Similar companies to Inozyme Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Inozyme Pharma? Inozyme Pharma's current market cap is $62.3M
Is Inozyme Pharma profitable? Yes, Inozyme Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.